Market Place
Sourcing Support
Instil Bio Reports Q3 2024 Financial Results & Corporate Update
13 Nov 2024 //
GLOBENEWSWIRE
Instil Bio And ImmuneOnco Announce PD-L1xVEGF Strategy
16 Sep 2024 //
GLOBENEWSWIRE
Instil Bio Reports Q2 2024 Results And Provides Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
Instil Bio And ImmuneOnco Partner On PD-L1xVEGF And CTLA-4 Antibodies
02 Aug 2024 //
PRESS RELEASE
Instil Bio Q1 2024 Financials, Corporate Update
10 May 2024 //
GLOBENEWSWIRE
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Instil Bio Announces Strategic Update
16 Jan 2024 //
GLOBENEWSWIRE
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
05 Dec 2023 //
GLOBENEWSWIRE
Instil Bio Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC
06 Nov 2023 //
GLOBENEWSWIRE
Instil Bio Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data
26 Jun 2023 //
GLOBENEWSWIRE
Instil Bio Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Instil Bio Reports 4Q & 2022 Financial Results orporate Update
31 Mar 2023 //
GLOBENEWSWIRE
More layoffs at Instil as cell therapy production shifts to UK
01 Feb 2023 //
FIERCE BIOTECH
Instil Bio Announces Extension of Cash Runway Beyond 2026 with R&D Operations
31 Jan 2023 //
GLOBENEWSWIRE
Instil Bio Announces Resumption of Trial of CoStAR-TIL Candidate ITIL-306
09 Jan 2023 //
GLOBENEWSWIRE
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program
08 Dec 2022 //
GLOBENEWSWIRE
Instil Bio takes the ax to its lead asset, cuts 60% of its staff
08 Dec 2022 //
FIERCEBIOTECH
Instil Bio Reports 3Q 2022 Financial Results and Provides Corporate Update
14 Nov 2022 //
GLOBENEWSWIRE
Instil Bio Announces Poster Presentations of CoStAR Platform at 2022 for (SITC)
08 Nov 2022 //
GLOBENEWSWIRE
Instil Bio halts subject enrolment in trials due to manufacturing issues
01 Nov 2022 //
CLINICALTRIALSARENA
Instil Announces Pause of Enrollment in Trials Related to Manufacturing
31 Oct 2022 //
GLOBENEWSWIRE
Instil Bio Announces First Patient Dosed with ITIL-306
18 Oct 2022 //
GLOBENEWSWIRE
Instil Bio to Present at Morgan Stanley Global Healthcare Conference
09 Sep 2022 //
GLOBENEWSWIRE
Instil Bio Reports Q2 2022 Financial Results and Provides Corporate Update
12 Aug 2022 //
PRESS RELEASE
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306
27 May 2022 //
GLOBENEWSWIRE
Instil Bio to Present Novel TIL Analytics at ASGCT
18 May 2022 //
GLOBENEWSWIRE
Instil Bio Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Instil Bio Reports Q4 and FY 2021 Financial Results
07 Mar 2022 //
GLOBENEWSWIRE
Instil Bio to Present at the Cowen 42nd Annual Health Care Conference
02 Mar 2022 //
GLOBENEWSWIRE
Instil Bio Announces Poster Presentations at the 2021 (SITC)
15 Nov 2021 //
GLOBENEWSWIRE
Instil Bio Presents Subset Analysis of Patients with Melanoma
16 Sep 2021 //
GLOBENEWSWIRE
Instil Bio to Present at Upcoming Investor Conferences in September 2021
01 Sep 2021 //
BIO SPACE
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
27 Apr 2021 //
GLOBENEWSWIRE
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking
13 Apr 2021 //
GLOBNEWSWIRE
Instil Bio Announces Closing of Initial Public Offering and Full Exercise
23 Mar 2021 //
GLOBENEWSWIRE
Cancer biotech Instil Bio raises deal size by 25% ahead of $312 million IPO
18 Mar 2021 //
NASDAQ
